Deciding Between Active Surveillance and Targeted Therapy in BRCA+ Prostate Cancer
Leonard G. Gomella, MD, discusses deciding between active surveillance and precision medicine in mutated prostate cancer.
Leonard G. Gomella, MD, the chair of the Department of Urology and director of the Sidney Kimmel Cancer Center Network at Thomas Jefferson University Hospital, discusses deciding between active surveillance of a patients with BRCA-mutated prostate cancer or treating with precision medicine approach.
According to Gomella, very few studies have been conducted that connect mutated disease to active surveillance. Patients with BRCA1/2 mutated prostate cancer are more likely to fall off of active surveillance. However, not a lot of guidelines exist when it comes to the subject.
Genetic alterations are integrated into surveillance decisions, according to Gomella. Genetic alterations in breast and ovarian cancer are more prevalent in women than men who develop prostate cancer. However, men who have a family history of breast or ovarian cancer should consider early prostate cancer screenings.
Capivasertib Improves PFS in PTEN-Deficient mHSPC
November 30th 2024Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Read More
